Holocene Advisors LP Sells 287,221 Shares of Icon Plc $ICLR

Holocene Advisors LP reduced its position in shares of Icon Plc (NASDAQ:ICLR) by 42.3% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 392,506 shares of the medical research company’s stock after selling 287,221 shares during the quarter. Holocene Advisors LP owned about 0.49% of Icon worth $68,689,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of ICLR. Private Trust Co. NA boosted its stake in Icon by 200.0% in the third quarter. Private Trust Co. NA now owns 141 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 94 shares during the last quarter. Ameriflex Group Inc. acquired a new position in shares of Icon in the 3rd quarter valued at $33,000. Wilmington Savings Fund Society FSB lifted its stake in shares of Icon by 153.4% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 332 shares of the medical research company’s stock valued at $58,000 after purchasing an additional 201 shares during the period. Pilgrim Partners Asia Pte Ltd acquired a new stake in shares of Icon during the third quarter worth $63,000. Finally, Johnson Financial Group Inc. bought a new stake in Icon in the third quarter valued at about $71,000. Institutional investors own 95.61% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on ICLR. Zacks Research cut Icon from a “hold” rating to a “strong sell” rating in a report on Wednesday, February 25th. TD Cowen upgraded shares of Icon from a “hold” rating to a “buy” rating and decreased their price objective for the company from $183.00 to $120.00 in a report on Wednesday, February 18th. Leerink Partners reiterated a “market perform” rating and issued a $105.00 target price on shares of Icon in a report on Thursday, February 12th. Citigroup decreased their price target on shares of Icon from $200.00 to $120.00 and set a “neutral” rating for the company in a report on Wednesday, March 11th. Finally, BMO Capital Markets reaffirmed a “market perform” rating and set a $100.00 price objective on shares of Icon in a research note on Thursday, February 12th. Six analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Icon has a consensus rating of “Hold” and a consensus target price of $146.80.

Icon Trading Down 0.7%

Shares of Icon stock opened at $97.61 on Tuesday. The stock has a market cap of $7.88 billion, a P/E ratio of 13.21, a P/E/G ratio of 2.52 and a beta of 1.36. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 0.31. Icon Plc has a 12-month low of $66.57 and a 12-month high of $211.00. The business’s 50 day moving average is $142.09 and its 200-day moving average is $164.85.

Icon Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.